B-cell posttransplant lymphoproliferative disorder isolated to the central nervous system is Epstein-Barr virus positive and lacks p53 and Myc expression by immunohistochemistry

2017 ◽  
Vol 61 ◽  
pp. 140-147 ◽  
Author(s):  
Andrew Sundin ◽  
Bartosz J. Grzywacz ◽  
Sophia Yohe ◽  
Michael A. Linden ◽  
Elizabeth L. Courville
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
B Cell ◽  
Lymphoproliferative Disorder ◽  
Epstein Barr Virus ◽  
Posttransplant Lymphoproliferative Disorder ◽  
Barr Virus ◽  
The Central Nervous System ◽  
Epstein Barr

scholarly journals Epstein–Barr Virus-Induced Post-Transplant Lymphoproliferative Disorder of the Central Nervous System Successfully Treated with Chemo-Immunotherapy

Viruses ◽  
2020 ◽  
Vol 12 (4) ◽  
pp. 416
Author(s):  
Hiroaki Inoue ◽  
Shinya Rai ◽  
Hirokazu Tanaka ◽  
J. Luis Espinoza ◽  
Maiko Komori-Inoue ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Aplastic Anemia ◽  
Lymphoproliferative Disorder ◽  
Epstein Barr Virus ◽  
Hematopoietic Stem ◽  
Post Transplant ◽  
Barr Virus ◽  
The Central Nervous System ◽  
Epstein Barr

Aplastic anemia is a rare blood disease characterized by the destruction of the hematopoietic stem cells (HSC) in the bone marrow that, in the majority of cases, is caused by an autoimmune reaction. Patients with aplastic anemia are treated with immunosuppressive drugs and some of them, especially younger individuals with a donor available, can be successfully treated with hematopoietic stem cell transplantation (HSCT). We report here a rare case of post-transplant lymphoproliferative disorder (PTLD) associated with Epstein–Barr virus (EBV) reactivation in a 30-year-old female patient who underwent allogeneic HSCT for severe aplastic anemia. The PTLD, which was diagnosed 230 days after transplantation, was localized exclusively in the central nervous system (specifically in the choroid plexus) and manifested with obvious signs of intracranial hypertension. After receiving three cycles of high dose methotrexate (HD-MTX) combined with rituximab, the patient achieved a complete clinical recovery with normalization of blood cell counts, no evidence of EBV reactivation, and no associated neurotoxicity.

Sign in / Sign up

Export Citation Format

Share Document